SYNTOCINON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Syntocinon, and when can generic versions of Syntocinon launch?
Syntocinon is a drug marketed by Novartis and Rtrx and is included in two NDAs.
The generic ingredient in SYNTOCINON is oxytocin. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the oxytocin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Syntocinon
A generic version of SYNTOCINON was approved as oxytocin by HIKMA on January 10th, 2007.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SYNTOCINON?
- What are the global sales for SYNTOCINON?
- What is Average Wholesale Price for SYNTOCINON?
Summary for SYNTOCINON
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 59 |
| Clinical Trials: | 129 |
| Patent Applications: | 5,144 |
| DailyMed Link: | SYNTOCINON at DailyMed |
Recent Clinical Trials for SYNTOCINON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Egymedicalpedia | N/A |
| Cairo University | Phase 4 |
| University of California, San Francisco | Phase 2 |
US Patents and Regulatory Information for SYNTOCINON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SYNTOCINON | oxytocin | INJECTABLE;INJECTION | 018245-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Rtrx | SYNTOCINON | oxytocin | SOLUTION;NASAL | 012285-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
